瘢痕疙瘩相关性瘙痒的发病机制及治疗研究进展

金以超; 王晓川; 敖春萍; 徐良恒

doi:10.12259/j.issn.2095-610X.S20241224

瘢痕疙瘩相关性瘙痒的发病机制及治疗研究进展

doi: 10.12259/j.issn.2095-610X.S20241224

云南省第一人民医院/昆明理工大学附属医院皮肤科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（82360447）；云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目（202101AY070001-248）。

详细信息

作者简介:
金以超（1980～），男，云南弥勒人，医学博士，副主任医师，主要从事皮肤肿瘤，瘢痕疙瘩，光动力研究工作

通讯作者:
徐良恒，E-mail：heng1178@163.com

中图分类号: R619⁺.6
计量
- 文章访问数: 642
- HTML全文浏览量: 328
- PDF下载量: 27
- 被引次数: 0
出版历程
- 收稿日期: 2024-08-23
- 网络出版日期: 2024-12-05
- 刊出日期: 2024-12-31

Pruritus in Keloid：Pathogenesis and Treatments

Dept. of Dermatology，The 1st People’s Hospital of Yunnan Province/ the Affiliated Hospital of Kunming University of Science and Technology，Kunming Yunnan 650032，China

摘要

摘要: 瘢痕疙瘩是在皮肤创面愈合过程中，成纤维细胞异常增殖、细胞外基质过度沉积而形成的皮肤良性病变，86%瘢痕疙瘩患者会伴有瘙痒感。然而，瘢痕疙瘩相关性瘙痒症状在临床治疗中却容易被忽视。就瘢痕疙瘩相关性瘙痒症状的发病机制及其治疗进行综述，以期为瘢痕疙瘩相关性瘙痒的控制提供有效的方案。
- 瘢痕疙瘩 /
- 瘙痒 /
- 炎症 /
- 治疗
Abstract: Keloids are benign skin lesions that form during the wound healing process due to abnormal proliferation of fibroblasts and excessive extracellular matrix deposition. It is reported that 86% of keloid patients experience pruritus; however, the symptom of pruritus associated with keloids is often overlooked in clinical treatment. Review the pathogenesis and treatment of pruritusin keloids, with the goal of providing effective strategies for its management.
- Keloid /
- Pruritus /
- Inflammation /
- Treatments

HTML全文

参考文献(44)

[1]	Jeschke M G,Wood F M,Middelkoop E,et al. Scars[J]. Nature Reviews Disease Primers,2023,9(1):1-16. doi: 10.1038/s41572-022-00413-2
[2]	Bijlard E,Kouwenberg C A E,Timman R,et al. Burden of Keloid Disease: A cross-sectional health-related quality of life assessment[J]. Acta Derm Venereol,2017,97(2):225-229. doi: 10.2340/00015555-2498
[3]	Kassi K,Kouame K,Kouassi A,et al. Quality of life in black African patients with keloid scars[J]. Dermatology Reports,2020,12(2):28-31.
[4]	Jumper N,Paus R,Bayat A. Functional histopathology of keloid disease[J]. Histol Histopathol,2015,30(2):1033-1057.
[5]	Yin S-L,Qin Z-L,Yang X. Role of periostin in skin wound healing and pathologic scar formation[J]. Chinese Medical Journal,2020,133(18):2236-2238. doi: 10.1097/CM9.0000000000000949
[6]	Hashimoto T,Mishra SK,Olivry T,Yosipovitch G. Periostin,an emerging player in itch sensation[J]. J Invest Dermatol,2021,141(10):2338-2343. doi: 10.1016/j.jid.2021.03.009
[7]	Bagabir R,Byers R J,Chaudhry I H,et al. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates[J]. The British Journal of Dermatology,2012,167(5):1053-1066. doi: 10.1111/j.1365-2133.2012.11190.x
[8]	Wang N,Liang H,Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance[J]. Frontiers in Immunology,2014,5(1):1-9.
[9]	Wu J,Del Duca E,Espino M,et al. RNA Sequencing Keloid Transcriptome Associates Keloids With Th2,Th1,Th17/Th22,and JAK3-Skewing[J]. Frontiers in Immunology,2020,11(1):177-180. doi: 10.3389/fimmu.2020.00177
[10]	Garcovich S,Maurelli M,Gisondi P,et al. Pruritus as a Distinctive Feature of Type 2 Inflammation[J]. Vaccines (Basel),2021,9(3):1-16.
[11]	Xu J,Zanvit P,Hu L,et al. The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching[J]. Immunity,2020,53(2):371-383. doi: 10.1016/j.immuni.2020.06.023
[12]	Datsi A,Steinhoff M,Ahmad F,et al. Interleukin-31: The “itchy” cytokine in inflammation and therapy[J]. Allergy,2021,76(10):2982-2997.
[13]	Wilgus T A,Wulff B C. The Importance of Mast Cells in Dermal Scarring[J]. Adv Wound Care (New Rochelle),2014,3(4):356-365.
[14]	Lee S S,Yosipovitch G,Chan Y H,et al. Pruritus,pain,and small nerve fiber function in keloids: A controlled study[J]. Journal of the American Academy of Dermatology,2004,51(6):1002-1006.
[15]	Tey H L,Maddison B,Wang H,et al. Cutaneous innervation and itch in keloids[J]. Acta Dermato-Venereologica,2012,92(5):529-531. doi: 10.2340/00015555-1336
[16]	Leal E C,Carvalho E,Tellechea A,et al. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype[J]. The American Journal of Pathology,2015,185(6):1638-1648. doi: 10.1016/j.ajpath.2015.02.011
[17]	Chen W,Fu X,Sun X,et al. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray[J]. The Journal of Surgical Research,2003,113(2):208-216. doi: 10.1016/S0022-4804(03)00188-4
[18]	Tomioka M,Stead R H,Nielsen L,et al. Nerve growth factor enhances antigen and other secretagogue-induced histamine release from rat peritoneal mast cells in the absence of phosphatidylserine[J]. The Journal of Allergy and Clinical Immunology,1988,82(4):599-607. doi: 10.1016/0091-6749(88)90971-2
[19]	Kanda N,Watanabe S. Histamine enhances the production of nerve growth factor in human keratinocytes[J]. The Journal of Investigative Dermatology,2003,121(3):570-577. doi: 10.1046/j.1523-1747.2003.12428.x
[20]	Mustoe T A,Cooter R D,Gold M H,et al. International clinical recommendations on scar management[J]. Plastic and Reconstructive Surgery,2002,110(2):560-571. doi: 10.1097/00006534-200208000-00031
[21]	Morelli Coppola M,Salzillo R,Segreto F,et al. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives[J]. Clinical,Cosmetic and Investigational Dermatology,2018,111:387-396. doi: 10.2147/CCID.S133672
[22]	Cedeno-Laurent F,Singer E M,Wysocka M,et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities[J]. Clinical immunology (Orlando,Fla. ),2015,158(1):1-7. doi: 10.1016/j.clim.2015.02.014
[23]	Yaseen B,Lopez H,Taki Z,et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma[J]. Rheumatology (Oxford,England),2020,59(9):2625-2636. doi: 10.1093/rheumatology/keaa195
[24]	Hashimoto T,Nattkemper L A,Kim H S,et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31,oncostatin M,IL-31 receptor alpha and oncostatin M receptor beta[J]. Experimental Dermatology,2021,30(6):804-810. doi: 10.1111/exd.14279
[25]	Brunner P M,Khattri S,Garcet S,et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis[J]. The Journal of Allergy and Clinical Immunology,2016,138(1):169-178. doi: 10.1016/j.jaci.2015.12.1323
[26]	Fowler E,Yosipovitch G. Chronic itch management: therapies beyond those targeting the immune system[J]. Annals of Allergy,Asthma & Immunology,Elsevier,2019,123(2): 158-165.
[27]	李峥,张兵,李巍,等. 加巴喷丁治疗深Ⅱ度烧伤后瘢痕瘙痒的临床效果[J]. 中华烧伤杂志,2015,31(3):177-180.
[28]	Lee H G,Grossman S K,Valdes-Rodriguez R,et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability[J]. Journal of the American Academy of Dermatology,2017,76(4):760-761. doi: 10.1016/j.jaad.2016.10.030
[29]	Eishi K,Bae S J,Ogawa F,et al. Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: possible target of mast cells[J]. The Journal of Dermatological Treatment,2003,14(4):248-252. doi: 10.1080/09546630310016808
[30]	Xiao Z,Zhang F,Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report[J]. Aesthetic Plastic Surgery,2009,33(3):409-412. doi: 10.1007/s00266-009-9334-z
[31]	Scala J,Vojvodic A,Vojvodic P,et al. Botulin toxin use in scars/Keloids treatment[J]. Open Access Macedonian Journal of Medical Sciences,2019,7(18):2979-2981. doi: 10.3889/oamjms.2019.783
[32]	Xiao Z,Zhang M,Liu Y,et al. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar[J]. Aesthetic Plastic Surgery,2011,35(5):802-807. doi: 10.1007/s00266-011-9690-3
[33]	Carmichael N M E,Dostrovsky J O,Charlton M P. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin[J]. Pain,2010,149(2):316-324. doi: 10.1016/j.pain.2010.02.024
[34]	Gupta S,Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids[J]. Dermatology (Basel,Switzerland),2002,204(2):130-132. doi: 10.1159/000051830
[35]	Aggarwal H,Saxena A,Lubana P S,et al. Treatment of keloids and hypertrophic scars using bleom[J]. Journal of Cosmetic Dermatology,2008,7(1):43-49. doi: 10.1111/j.1473-2165.2008.00360.x
[36]	Zhu R,Yue B,Yang Q,et al. The effect of 595 nm pulsed dye laser on connective tissue growth factor (CTGF) expression in cultured keloid fibroblasts[J]. Lasers in Surgery and Medicine,2015,47(2):203-209. doi: 10.1002/lsm.22334
[37]	Connell P G,Harland C. Treatment of keloid scars with pulsed dye laser and intralesional steroid[J]. Journal of Cutaneous Laser Therapy,2000,2(3):147-150. doi: 10.1080/14628830050516407
[38]	Li W B,Liu S,Zhang M Z,et al. Hyperbaric oxygen therapy relieved pruritus and pain of keloid patients[J]. American Journal of Translational Research,2020,12(2):574-582.
[39]	Klotz T,Kurmis R,Munn Z,et al. Moisturisers in scar management following burn: A survey report[J]. Burns: Journal of the International Society for Burn Injuries,2017,43(5):965-972. doi: 10.1016/j.burns.2017.01.021
[40]	De Decker I,Hoeksema H,Vanlerberghe E,et al. Occlusion and hydration of scars: moisturizers versus silicone gels[J]. Journal of the International Society for Burn Injuries,2023,49(2):365-379. doi: 10.1016/j.burns.2022.04.025
[41]	Nguyen D A,Thai E,Weis S E. Management of Keloid-Associated Pruritus With Topical Crisaborole 2% Ointment: A Case Report[J]. HCA Healthcare Journal of Medicine,2024,5(2):139-143.
[42]	Bissonnette R,Pavel A B,Diaz A,et al. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial[J]. The Journal of Allergy and Clinical Immunology,2019,144(5):1274-1289. doi: 10.1016/j.jaci.2019.06.047
[43]	Diaz A,Tan K,He H,et al. Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy[J]. Journal of the European Academy of Dermatology and Venereology,2020,34(4):e161-e164.
[44]	Wong A J S,Song E J. Dupilumab as an adjuvant treatment for keloid-associated symptoms[J]. JAAD Case Reports,2021,13(1):73-74. doi: 10.1016/j.jdcr.2021.04.034

相关文章(20)

[1]	丁鹏, 李嘉, 赵小丹, 赵洁, 苗昌荣. miR-193a-5p调控IL-33/ST2信号通路对慢性心力衰竭大鼠心功能的保护作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250506
[2]	贾政, 邢正江, 刘茜, 杜义斌, 李冰, 解英, 赵义. 建立大鼠心肌缺血与体外CMECs缺氧模型-观察对冠脉微循环的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241106
[3]	聂绍燕, 范苏苏, 朱钰珊, 彭学容, 王洋, 张旋. 喜炎平注射液对脂多糖诱导的急性肺损伤小鼠的保护作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241105
[4]	李妍平, 董小林, 李青芸, 李红梅, 魏欢, 曾毅. miR-21-5p通过抑制STAT3缓解OGD诱导的HT22细胞炎症和凋亡并促进增殖, 昆明医科大学学报.
[5]	江华维, 刘霞, 王艳, 章敏慧, 尹维丹, 张利伟. 翼状胬肉发病机制的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230125
[6]	徐凡, 郭方圆, 何燕, 魏向群. 子宫腺肌病患者外周血血细胞及凝血功能的临床分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211124
[7]	杨丽晗, 张志毕, 杨晖, 杨江兰, 虎丹, 杨晓丽, 罗朝昱, 张媛, 张荣平. 两种血竭凝胶抗炎抗菌效果比较, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210134
[8]	杨绍艳, 伍路, 张素仙. miRNAs在子宫内膜异位症发生发展中的作用研究进展, 昆明医科大学学报.
[9]	李娜, 涂颖, 熊英, 能亚杰, 李红宾, 梁红敏. 慢性瘙痒患者生活行为方式与皮肤生理功能的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201222
[10]	李玉鹏, 角建林, 吕乐春. 芦丁对瘢痕疙瘩成纤维细胞增殖的影响, 昆明医科大学学报.
[11]	张福厚. 半乳糖凝集素与静脉血栓形成机制的研究进展, 昆明医科大学学报.
[12]	李艳. 天麻成分对羟基苯甲醇抗实验性脑血栓形成及抗炎作用研究, 昆明医科大学学报.
[13]	张毅. 骨康贴治疗骨折疼痛临床体会, 昆明医科大学学报.
[14]	刘艳. 炎症性肠病与生育, 昆明医科大学学报.
[15]	张梦思. 儿童下肢烧伤后严重瘢痕挛缩临床治疗体会, 昆明医科大学学报.
[16]	方克伟. 腺性输尿管炎5例临床诊断与治疗, 昆明医科大学学报.
[17]	苏莹. 慢性乙型肝炎患者外周血Th17细胞的变化及意义, 昆明医科大学学报.
[18]	柏青. 剖宫产瘢痕妊娠临床分析, 昆明医科大学学报.
[19]	李洁. He-Ne激光局部照射治疗外阴鳞状上皮细胞增生165例疗效观察, 昆明医科大学学报.
[20]	李玉晓. 克拉霉素治疗FESS后鼻窦黏膜迁延性炎症的临床研究, 昆明医科大学学报.